Objective To analyze the clinical features and laboratory test results of patients with autoimmune hepatitis ( AIH) - primary biliary cirrhosis ( PBC) overlap syndrome, as well as their correct diagnosis rate and time to diagnosis. Methods Fifty- three patients who were diagnosed by liver biopsy as having AIH- PBC overlap syndrome from January 2009 to June 2013 were selected as subjects; 53 AIH patients and 53 PBC patients were selected as control groups. Their clinical manifestations, laboratory test results, and diagnosis on admission were retrospectively analyzed. Comparison of normally distributed quantitative data between groups was made by one- way analysis of variance, and multiple comparisons were made by SNK- q test; comparison of qualitative data between groups was made using R × C contingency table, and multiple comparisons were made by Scheffe's confidence interval test. Results The 53 patients with AIH- PBC overlap syndrome had a serum alanine aminotransferase level of 173. 65 ± 52. 08 U / L, a serum total bilirubin level of 38. 07 ± 6. 82 μmol / L, a serum alkaline phosphatase ( ALP) level of 293. 81 ± 28. 89 U / L, and a serum gamma- glutamyl transpeptidase level of 57. 57 ± 78. 84 U / L. ALP showed significant difference between the patients with AIH- PBC overlap syndrome and control groups. The serum level of immunoglobulin M in overlap syndrome patients was 3. 33 ± 2. 12 g / L, which was significantly different from those of two control groups. Of the 53 overlap syndrome patients, 27 were positive for anti- mitochondrial antibody- M2, and the positive rate was significantly different from those of two control groups. Without liver biopsy, the correct diagnosis rate was the lowest ( 52. 83%) , and it took the longest time ( 8 ± 7. 7 d) to confirm the diagnosis on admission. Conclusion The clinical manifestations of patients with AIH- PBC overlap syndrome are more similar to those of PBC patients, but their biochemical test results are more similar to those of AIH patients. AIH- PBC overlap syndrome has the clinical features of both AIH and PBC.
[1]RUST C, BEUERS U.Overlap syndromes among autoimmune liver diseases[J].World J Gastroenterol, 2008, 14 (21) :3368-3373.
|
[2]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.
|
[3]HENNES EM, ZENIYA M, CZAJA AJ, et al.Simplified criteria for the diagnosis of autoimmune hepatitis[J].Hepatology, 2008, 48 (1) :169-176.
|
[4]CHU JD, ZHU JY, GAO ZJ, et al.Observation of clinical feature and curative efficacy on autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J].J Clin Hepatol, 2012, 28 (5) :343-348. (in Chinese) 楚金东, 朱疆依, 高正军, 等.自身免疫性肝炎和原发性胆汁性肝硬化重叠综合征的临床特征及疗效观察[J].临床肝胆病杂志, 2012, 28 (5) :343-348.
|
[5]ABDOLLAHI MR, SOMI MH, FARAJI E.Role of international criteria in the diagnosis of autoimmune hepatitis[J].World J Gastroenterol, 2013, 19 (23) :3629-3633.
|
[6]WANG Q, SELMI C, ZHOU X, et al.Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis[J].J Autoimmun, 2013, 41:140-145.
|
[7]SCHRAMM C, LOHSE AW.Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis[J].Clin Rev Allergy Immunol, 2005, 28 (2) :105-114.
|
[1] | Yang Ning, Liu YanSheng, Han Ying. Diagnosis and treatment of primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Journal of Clinical Hepatology, 2020, 36(3): 697-700. doi: 10.3969/j.issn.1001-5256.2020.03.051 |
[2] | Ni Ping, Fan XiaoLi, Yang Li. Current status of research on overlap syndrome of autoimmune liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 743-748. doi: 10.3969/j.issn.1001-5256.2020.04.006 |
[3] | Shu YanYun, Pan XiaoLi, Song YuHu, Ye Jin. Clinical features of autoimmune hepatitis and primary biliary cholangitis: A comparative analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 354-358. doi: 10.3969/j.issn.1001-5256.2019.02.022 |
[4] | Huang ChunYang, Chen Jie, Liu YanMin, Dan Jing. Role of intestinal flora in the development/progression and treatment of autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 205-207. doi: 10.3969/j.issn.1001-5256.2019.01.045 |
[5] | Li ShuXiang, Duan WeiJia, Zhang Dong, You Hong, Jia JiDong. Research advances in autoimmune hepatitis and primary biliary cholangitis in 2017[J]. Journal of Clinical Hepatology, 2018, 34(7): 1569-1572. doi: 10.3969/j.issn.1001-5256.2018.07.044 |
[6] | Tian Hui. Rheumatic and skin manifestations associated with autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(9): 2021-2026. doi: 10.3969/j.issn.1001-5256.2018.09.041 |
[7] | Li YanQing, Dong HongJing, Liu XiaoWen, Gao YanHang. Latest clinical advances in autoimmune hepatitis in special populations and special types of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1338-1342. doi: 10.3969/j.issn.1001-5256.2018.06.044 |
[8] | Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008 |
[9] | Shang Jia, Ning HuiBin. Research progress in diagnosis and treatment of autoimmune liver disease overlap syndrome[J]. Journal of Clinical Hepatology, 2015, 31(2): 174-177. doi: 10.3969/j.issn.1001-5256.2015.02.007 |
[10] | Li YuanYuan, Wang LiFeng, Geng Hua, Yu ShuangJie, Lin Hu, Lu: Sa, Chen LiMing, Zhang Zheng, Wang FuSheng. Changes in frequencies of peripheral blood lymphocyte subsets and their clinical significance in patients with autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2014, 30(5): 409-412. doi: 10.3969/j.issn.1001-5256.2014.05.006 |
[11] | Sun LiMei, Zhao YanMing, Wang YiPeng, Zhao DanTong, Zhang HaiPing, Li ZhuoMin, Wang Yi, Ma YinXue, Yan HuiPing, Liu YanMin. Analysis of clinical significance of combined antigen screening reagents for autoimmune liver disease[J]. Journal of Clinical Hepatology, 2014, 30(5): 405-408. doi: 10.3969/j.issn.1001-5256.2014.05.005 |
[12] | Ye Qing, Han Tao, Li Ning. Clinical value of serum soluble intercellular adhesion molecule-1 in patients with primary biliary cirrhosis and autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(5): 417-420. doi: 10.3969/j.issn.1001-5256.2014.05.008 |
[13] | Lang ZhenWei. Pathological advances in autoimmune liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 326-331. |
[14] | Chu JinDong, Zhu JiangYi, Gao ZhengJun, Zhu ShaoHua, Dong XuYang, Han ZheYi, Shi YongQuan, Zhou XinMin, Han Ying. Observation of clinical feature and curative efficacy on autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2012, 28(5): 343-348. |
[15] | Shu HuiJun, Zhu Feng, Zhang LiXian. Comparison of the simplified criteria and conventional criteria for the diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2011, 27(9): 980-984. |
[16] | Wang TaiLing, Zhao XinYan. Pathological features of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2011, 27(6): 577-580. |
[17] | Yan HuiPing. Detection of autoantibodies and standardization of result report[J]. Journal of Clinical Hepatology, 2011, 27(6): 595-597. |
[18] | Duan WeiJia, Jia JiDong. Clinical advances in autoimmune liver disease in 2010[J]. Journal of Clinical Hepatology, 2011, 27(6): 567-569. |
[19] | Feng ShaoChun, Wang Shan, Chen Hong. Study on the treatment of overlap syndrome of autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1069-1071. |
[20] | Gao MinZhao, Liu YuLan. Clinical analysis of 187 patients with autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1066-1068+1080. |